Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501735 · ClinicalTrials.gov registry record · Phase 2
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00501735 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 144 participants.
The verdict
NCT00501735, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of CTCL with a requirement for maintenance of such objective response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally, this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB, III, or IVA treated with oral forodesine.
Interventions
- DRUG Forodesine 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501735
The ClinicalTrials.gov registry entry for NCT00501735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Forodesine 200 mg is the first listed.
NCT00501735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501735 about?
NCT00501735 is a clinical study titled "Forodesine in the Treatment of Cutaneous T-Cell Lymphoma". This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up to 50 sites in North America, Europe and Australia. This study is designed to assess objective response (OR) \[complete response (CR) or partial response (PR)\] in subjects with cutaneous manifestations of ...
What is the current status of trial NCT00501735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2007-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00501735?
The interventions under investigation include: Forodesine 200 mg (DRUG).
Who is sponsoring clinical trial NCT00501735?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.